Naresh Punjabi, MD
Pulmonary Disease · Miami, FLNPI 1447297411
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Amgen at 58.8% of the total. 2025 is the largest year on record at $3,987, more than ten times the $21 reported in 2020.
Across 40 payments — averaging $167.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Inspire Medical Systems, Inc.$2K
- Harmony Biosciences LLC$386
- Resmed Corp$141
- 4dmedical USA Inc$140
- Jazz Pharmaceuticals Inc.$91
- plus $174 from 4 others
Across 26 payments — averaging $18,185 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Resmed Corp$381K
- Philips North America LLC$50K
- Abbott$25K
- Masimo Corporation$10K
- Dexcom, Inc.$6K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $557 from 1 others
What the payments were for
- Consulting fees$3,94259%
- Travel & lodging$1,36520%
- Food & beverage$1,33520%
- Education$601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $3,942 |
| Inspire Medical Systems, Inc. | 13 | $1,829 |
| Harmony Biosciences LLC | 8 | $386 |
| Resmed Corp | 3 | $141 |
| 4dmedical USA Inc | 3 | $140 |
| Jazz Pharmaceuticals Inc. | 4 | $91 |
| Inogen, Inc. | 5 | $76 |
| Baxter Healthcare | 1 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| United Therapeutics Corporation | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,703 in reported general payments places this provider in the 65th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxepin Hcl | 39 | $1,044 |
| Zolpidem Tartrate | 23 | $223 |
| Eszopiclone | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Raul ValorMiami$232K
- Shirin ShafazandMiami$193K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Jaime AvecillasMiami$70K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.